TransCode submits IND amendment for Phase 2a trial of TTX-MC138 in colorectal cancer

Transcode Therapeutics, Inc.

IND amendment filed with FDA for Phase 2a dose-expansion trial of TTX-MC138 in colorectal cancer patients with ctDNA-positive MRD.
Trial to enroll up to 45 patients who completed curative-intent therapy; expected start in first half 2026.
Study conducted by Quantum Leap Healthcare within PRE-I-SPY platform, its first expansion into colorectal cancer.
Principal Investigator Dr. Paula Pohlmann of MD Anderson Cancer Center leads the trial.
Collaboration with Quantum Leap and support from Colorectal Cancer Alliance; trial ID NCT05868226.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.